Results 51 to 60 of about 17,947 (225)
Management of ring chromosome 20 syndrome: Narrative review and consensus recommendations
Epilepsia, EarlyView.Abstract Ring chromosome 20 (ring 20) is a rare genetic condition usually presenting as developmental and epileptic encephalopathy. The disease is caused by fusion of the long and short arms of chromosome 20. Patients are symptomatic even if there is no loss of genetic material.
Asma Khamis +8 more
wiley +1 more source
Corticocortical evoked potential amplitude is altered by cortical stimulation in epilepsy
Epilepsia, EarlyView.Abstract Objective Neurostimulation is an established therapy for drug‐resistant epilepsy, but optimizing stimulation parameters remains a major challenge. Corticocortical evoked potential (CCEP) amplitude may serve as an immediate biomarker of neurostimulation effects, enabling rapid parameter optimization.
Bethany J. Stieve +4 more
wiley +1 more source
Epilepsia, EarlyView.Abstract Perampanel (PER) is a third‐generation antiseizure medication (ASM) with a well‐established concentration–effect relationship. Saliva represents a non‐invasive alternative to plasma for therapeutic drug monitoring (TDM) of PER, as it reflects the free plasma fraction.
Valentina Franco +14 more
wiley +1 more source
Efficacy and Tolerance of Synthetic Cannabidiol for Treatment of Drug Resistant Epilepsy
Frontiers in Neurology, 2019 Objective: Controlled and open label trials have demonstrated efficacy of cannabidiol for certain epileptic encephalopathies. However, plant derived cannabidiol products have been used almost exclusively. Efficacy of synthetically derived cannabidiol has
Kerstin A. Klotz +6 more
doaj +1 more source
Epilepsia, EarlyView.Abstract Objective Developmental and epileptic encephalopathies (DEEs) are characterized by drug‐resistant seizures and developmental slowing/regression. We examined the efficacy and tolerability of fenfluramine (FFA) in pediatric and adult patients with Lennox–Gastaut syndrome (LGS), Dravet syndrome (DS), and other DEEs.
Vicente Villanueva +29 more
wiley +1 more source
Precision therapies for genetic epilepsies in 2025: Promises and pitfalls
Epilepsia Open, EarlyView.Abstract By targeting the underlying etiology, precision therapies offer an exciting paradigm shift to improve the stagnant outcomes of drug‐resistant epilepsies, including developmental and epileptic encephalopathies. Unlike conventional antiseizure medications (ASMs) which only treat the symptoms (seizures) but have no effect on the underlying ...
Shuyu Wang +3 more
wiley +1 more source
The Therapeutic Crossroad Between Mitochondria and Cannabidiol: A Mini-Review
BiologyCannabidiol is a non-psychoactive compound originating from Cannabis sativa L., with a promising therapeutic profile that influences numerous cellular processes.
Mihaela Jorgovan +5 more
doaj +1 more source
Cannabidiol as a treatment for epilepsy [PDF]
Journal of Neurology, 2017 Despite an increasing number of anti-epileptic drugs (AEDs), the proportion of drug-resistant cases of epilepsy has remained fairly static at around 30% and the search for new and improved AEDs continues. Cannabis has been used as a medical treatment for epilepsy for thousands of years; it contains many active compounds, the most important being ...
Pickrell, William O., Robertson, Neil P.
openaire +5 more sources
Epileptic drop attacks: More than just atonic seizures
Epilepsia Open, EarlyView.Abstract “Drop attacks” are not officially defined by the International League Against Epilepsy. Seizures are characterized by a sudden loss of control over the trunk and posture, leading to falls and injuries, and resolving within a few seconds. Accurately diagnosing the type of seizure is usually difficult due to limitations in clinical documentation
Tomonori Ono +3 more
wiley +1 more source